Galmed Historical Balance Sheet

GLMD Stock  USD 2.76  0.11  3.83%   
Trend analysis of Galmed Pharmaceuticals balance sheet accounts such as Short and Long Term Debt Total of 39 K or Other Current Liab of 673 K provides information on Galmed Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Galmed Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Galmed Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Galmed Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Galmed Pharmaceuticals is a good buy for the upcoming year.

Galmed Pharmaceuticals Inventory

137,655

  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galmed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.

About Galmed Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Galmed Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Galmed Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Galmed Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Galmed currently owns. An asset can also be divided into two categories, current and non-current.

Galmed Pharmaceuticals Balance Sheet Chart

At present, Galmed Pharmaceuticals' Accounts Payable is projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 3.6 M, whereas Total Assets are forecasted to decline to about 15.8 M.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Assets

Total assets refers to the total amount of Galmed Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Galmed Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.
Most accounts from Galmed Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Galmed Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galmed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.At present, Galmed Pharmaceuticals' Accounts Payable is projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 3.6 M, whereas Total Assets are forecasted to decline to about 15.8 M.
 2021 2022 2023 2024 (projected)
Short and Long Term Debt Total229K44K41K39.0K
Total Assets36.6M16.6M16.6M15.8M

Galmed Pharmaceuticals balance sheet Correlations

-0.210.68-0.37-0.29-0.21-0.22-0.320.280.37-0.24-0.23-0.420.31-0.19-0.11-0.450.66-0.05-0.36-0.07-0.44-0.19-0.39-0.42-0.47
-0.21-0.430.660.581.00.470.42-0.77-0.290.580.76-0.080.151.00.490.66-0.50.530.620.460.151.00.540.080.37
0.68-0.43-0.64-0.6-0.43-0.51-0.480.370.72-0.55-0.3-0.540.3-0.4-0.38-0.820.98-0.14-0.75-0.3-0.71-0.41-0.67-0.56-0.61
-0.370.66-0.640.780.630.750.26-0.41-0.660.720.380.26-0.190.640.620.82-0.710.270.790.620.280.640.420.460.29
-0.290.58-0.60.780.530.630.52-0.18-0.60.990.140.16-0.060.560.850.72-0.570.420.70.940.380.570.530.270.51
-0.211.0-0.430.630.530.440.4-0.79-0.270.530.78-0.070.141.00.440.65-0.50.520.610.40.151.00.530.080.35
-0.220.47-0.510.750.630.440.11-0.24-0.660.550.210.25-0.030.450.40.78-0.480.190.780.530.390.460.320.370.1
-0.320.42-0.480.260.520.40.11-0.44-0.090.520.41-0.070.310.420.560.37-0.450.390.270.410.520.420.72-0.150.9
0.28-0.770.37-0.41-0.18-0.79-0.24-0.440.01-0.15-1.00.11-0.16-0.77-0.06-0.40.46-0.4-0.3-0.01-0.13-0.77-0.520.03-0.42
0.37-0.290.72-0.66-0.6-0.27-0.66-0.090.01-0.580.04-0.760.54-0.24-0.45-0.860.69-0.06-0.91-0.43-0.71-0.25-0.15-0.8-0.27
-0.240.58-0.550.720.990.530.550.52-0.15-0.580.110.14-0.030.560.880.68-0.510.460.680.940.360.570.50.240.49
-0.230.76-0.30.380.140.780.210.41-1.00.040.11-0.150.190.770.040.35-0.390.410.26-0.010.080.760.48-0.080.38
-0.42-0.08-0.540.260.16-0.070.25-0.070.11-0.760.14-0.15-0.87-0.12-0.030.5-0.49-0.040.520.020.69-0.12-0.240.950.3
0.310.150.3-0.19-0.060.14-0.030.31-0.160.54-0.030.19-0.870.180.13-0.210.280.11-0.250.0-0.270.180.46-0.9-0.1
-0.191.0-0.40.640.561.00.450.42-0.77-0.240.560.77-0.120.180.480.63-0.480.530.590.450.121.00.540.030.35
-0.110.49-0.380.620.850.440.40.56-0.06-0.450.880.04-0.030.130.480.55-0.350.430.570.840.260.480.440.090.41
-0.450.66-0.820.820.720.650.780.37-0.4-0.860.680.350.5-0.210.630.55-0.830.270.980.490.690.640.50.580.44
0.66-0.50.98-0.71-0.57-0.5-0.48-0.450.460.69-0.51-0.39-0.490.28-0.48-0.35-0.83-0.13-0.75-0.25-0.65-0.48-0.67-0.53-0.57
-0.050.53-0.140.270.420.520.190.39-0.4-0.060.460.41-0.040.110.530.430.27-0.130.250.430.170.530.24-0.020.37
-0.360.62-0.750.790.70.610.780.27-0.3-0.910.680.260.52-0.250.590.570.98-0.750.250.510.660.60.390.610.34
-0.070.46-0.30.620.940.40.530.41-0.01-0.430.94-0.010.020.00.450.840.49-0.250.430.510.170.460.310.130.36
-0.440.15-0.710.280.380.150.390.52-0.13-0.710.360.080.69-0.270.120.260.69-0.650.170.660.170.120.330.530.67
-0.191.0-0.410.640.571.00.460.42-0.77-0.250.570.76-0.120.181.00.480.64-0.480.530.60.460.120.550.040.35
-0.390.54-0.670.420.530.530.320.72-0.52-0.150.50.48-0.240.460.540.440.5-0.670.240.390.310.330.55-0.240.53
-0.420.08-0.560.460.270.080.37-0.150.03-0.80.24-0.080.95-0.90.030.090.58-0.53-0.020.610.130.530.04-0.240.2
-0.470.37-0.610.290.510.350.10.9-0.42-0.270.490.380.3-0.10.350.410.44-0.570.370.340.360.670.350.530.2
Click cells to compare fundamentals

Galmed Pharmaceuticals Account Relationship Matchups

Galmed Pharmaceuticals balance sheet Accounts

201920202021202220232024 (projected)
Common Stock Shares Outstanding1.4M1.4M1.6M1.7M230.8K219.3K
Total Assets77.1M52.4M36.6M16.6M16.6M15.8M
Other Current Liab892K935K966K1.0M830K673.0K
Total Current Liabilities6.9M8.0M5.9M3.1M2.8M4.0M
Total Stockholder Equity69.9M44.2M30.5M13.4M13.9M13.2M
Property Plant And Equipment Net709K570K551K337K125K118.8K
Net Debt(15.6M)(6.7M)(2.7M)(2.0M)(2.8M)(3.0M)
Retained Earnings(106.9M)(135.7M)(168.2M)(186.0M)(193.0M)(183.3M)
Accounts Payable6.0M7.0M4.9M2.6M1.9M3.2M
Cash15.9M6.9M2.9M2.0M2.9M2.7M
Non Current Assets Total709K570K551K1.8M3.4M3.6M
Cash And Short Term Investments75.5M50.9M34.8M13.8M12.6M12.0M
Net Receivables827K812K1.1M124K165K156.8K
Liabilities And Stockholders Equity77.1M52.4M36.6M16.6M16.6M15.8M
Other Current Assets28.1M925K1.2M668K432K410.4K
Other Stockholder Equity176.7M179.5M198.8M200.1M207.1M135.2M
Total Liab7.3M8.2M6.1M3.1M2.8M4.4M
Property Plant And Equipment Gross709K570K551K1.3M1.1M678.5K
Total Current Assets76.4M51.8M36.1M14.7M13.2M12.6M
Accumulated Other Comprehensive Income35K272K(171K)(745K)(454K)(431.3K)
Property Plant Equipment194K709K570K337K387.6K519.1K
Net Tangible Assets15.8M87.9M69.9M44.2M50.8M38.5M
Short Term Investments59.6M43.9M31.9M11.8M9.8M9.3M
Net Invested Capital69.9M44.2M30.5M13.4M13.9M13.2M
Net Working Capital69.5M43.8M30.2M11.6M10.5M10.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Galmed Pharmaceuticals is a strong investment it is important to analyze Galmed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Galmed Pharmaceuticals' future performance. For an informed investment choice regarding Galmed Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galmed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galmed Pharmaceuticals. If investors know Galmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
69.72
Return On Assets
(0.29)
Return On Equity
(0.53)
The market value of Galmed Pharmaceuticals is measured differently than its book value, which is the value of Galmed that is recorded on the company's balance sheet. Investors also form their own opinion of Galmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Galmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Galmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.